So far the therapeutic potential of selective inhibition of GPC1 for NSCLC treatment has not been documented, partly because of the unclear clinicopathological significance and diagnostic role of GPC1 in NSCLC [22, 23]. The gene discussed is GPC1; the disease is non-small cell lung carcinoma.